15 July 2019 - - Indian drugmaker Sun Pharmaceutical Industries Ltd. (NSE: SUNPHARMA) (BSE: 524715) has launched in the US market Ezallor Sprinkle (rosuvastatin) capsules for the treatment of three types of elevated lipid disorders in people who have difficulty swallowing, a problem that is estimated to affect approximately 30-35% of long-term care residents, the company said.
Ezallor Sprinkle is indicated as an adjunct to diet for the treatment of adult patients with hypertriglyceridemia, as an adjunct to diet for the treatment of adult patients with primary dysbetalipoproteinemia (type III hyperlipoproteinemia), and as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or as monotherapy if such treatments are unavailable, to reduce LDL-C, total cholesterol, and ApoB in adult patients with homozygous familial hypercholesterolemia.
It has not been studied in Fredrickson type I and V dyslipidemias.
Ezallor Sprinkle is formulated as extended-release-coated pellets that may be sprinkled over soft food such as applesauce, can be swallowed whole, or administered via a nasogastric tube to facilitate long-term, once-daily administration.
It joins Kapspargo Sprinkle (metoprolol succinate) extended-release capsules as the second product in the Sun Pharma portfolio designed for individuals in long-term care.
Ezallor Sprinkle is contraindicated in patients with any known hypersensitivity to rosuvastatin, which may include rash, pruritus, urticaria, and angioedema; patients with active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels, and females who are pregnant or breastfeeding. In the controlled clinical trials database, the most common adverse reactions with rosuvastatin were headache, myalgia, abdominal pain, asthenia, and nausea.
Sun Pharmaceutical Industries Inc., USA is a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd, a global specialty generic company based in Mumbai, which provides medicines for patients in more than 100 countries around the world.
The company's global presence is supported by 44 manufacturing facilities spread across six continents, R and D centers across the globe and a multi-cultural workforce comprising over 50 nationalities.
In India, the company enjoys leadership across 10 different classes of doctors with 30 brands featuring amongst the top 300 pharmaceutical brands.
Its footprint across emerging markets covers over 100 markets and 6 markets in Western Europe, and our Global Consumer Healthcare business is ranked amongst the top 10 across three global markets.
Sun Pharma's API business footprint is strengthened through 14 world-class API manufacturing facilities across the globe. It fosters excellence through innovation supported by strong R and D capabilities comprising about 2,000 scientists and R and D investments of approximately 8% of annual revenues.